In summary, EGFRvIII expression increased the de novo resistance of breast cancer cells against trastuzumab, and the feedback activation of STAT3 caused by trastuzumab also contributed to acquired resistance in EGFRvIII+HER2+ breast cancers. Here, ERBB2 is linked to breast cancer.